CA3226916A1 - Treatment of non-cystic fibrosis bronchiectasis - Google Patents
Treatment of non-cystic fibrosis bronchiectasis Download PDFInfo
- Publication number
- CA3226916A1 CA3226916A1 CA3226916A CA3226916A CA3226916A1 CA 3226916 A1 CA3226916 A1 CA 3226916A1 CA 3226916 A CA3226916 A CA 3226916A CA 3226916 A CA3226916 A CA 3226916A CA 3226916 A1 CA3226916 A1 CA 3226916A1
- Authority
- CA
- Canada
- Prior art keywords
- cms
- ncfb
- cba
- treatment
- pulmonary
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Dispersion Chemistry (AREA)
- Otolaryngology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21189819.2A EP4129322A1 (en) | 2021-08-05 | 2021-08-05 | Treatment of non-cystic fibrosis bronchiectasis |
| EP21189819.2 | 2021-08-05 | ||
| PCT/EP2022/071960 WO2023012280A1 (en) | 2021-08-05 | 2022-08-04 | Treatment of non-cystic fibrosis bronchiectasis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3226916A1 true CA3226916A1 (en) | 2023-02-09 |
Family
ID=77226670
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3226916A Pending CA3226916A1 (en) | 2021-08-05 | 2022-08-04 | Treatment of non-cystic fibrosis bronchiectasis |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20240342239A1 (https=) |
| EP (2) | EP4129322A1 (https=) |
| JP (1) | JP2024527021A (https=) |
| CN (1) | CN117794559A (https=) |
| AU (1) | AU2022324695A1 (https=) |
| BR (1) | BR112024001945A2 (https=) |
| CA (1) | CA3226916A1 (https=) |
| WO (1) | WO2023012280A1 (https=) |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2343122B (en) | 1998-10-26 | 2003-01-08 | Medic Aid Ltd | Improvements in and relating to nebulisers |
-
2021
- 2021-08-05 EP EP21189819.2A patent/EP4129322A1/en not_active Withdrawn
-
2022
- 2022-08-04 WO PCT/EP2022/071960 patent/WO2023012280A1/en not_active Ceased
- 2022-08-04 EP EP22761160.5A patent/EP4380592A1/en active Pending
- 2022-08-04 AU AU2022324695A patent/AU2022324695A1/en active Pending
- 2022-08-04 CN CN202280053442.5A patent/CN117794559A/zh active Pending
- 2022-08-04 BR BR112024001945A patent/BR112024001945A2/pt unknown
- 2022-08-04 US US18/294,688 patent/US20240342239A1/en active Pending
- 2022-08-04 CA CA3226916A patent/CA3226916A1/en active Pending
- 2022-08-04 JP JP2024504780A patent/JP2024527021A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4129322A1 (en) | 2023-02-08 |
| CN117794559A (zh) | 2024-03-29 |
| WO2023012280A1 (en) | 2023-02-09 |
| JP2024527021A (ja) | 2024-07-19 |
| BR112024001945A2 (pt) | 2024-04-30 |
| US20240342239A1 (en) | 2024-10-17 |
| EP4380592A1 (en) | 2024-06-12 |
| AU2022324695A1 (en) | 2024-02-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ratjen et al. | Aminoglycoside therapy against Pseudomonas aeruginosa in cystic fibrosis: a review | |
| JP2008503500A (ja) | 気管支感染症の治療法 | |
| Elborn et al. | Bronchiectasis and inhaled tobramycin: a literature review | |
| Bourdet et al. | Key concepts | |
| Siafakas et al. | Management of acute exacerbation of chronic obstructive pulmonary disease | |
| Mandelberg et al. | Nebulized wet aerosol treatment in emergency department—is it essential?: Comparison with large spacer device for metered-dose inhaler | |
| Schwarz et al. | Tobramycin safety and efficacy review article | |
| US20240342239A1 (en) | Treatment of non-cystic fibrosis bronchiectasis | |
| US12178841B2 (en) | Treatment of non-cystic fibrosis bronchiectasis | |
| Amirav et al. | Primary ciliary dyskinesia: prospects for new therapies, building on the experience in cystic fibrosis | |
| Falagas et al. | Local administration of polymyxins into the respiratory tract for the prevention and treatment of pulmonary infections in patients without cystic fibrosis | |
| US7973029B2 (en) | Inhaled aztreonam lysine for the treatment of deficits in health-related quality-of-life in lung diseases | |
| O'sullivan et al. | Inhaled aztreonam | |
| EA052469B1 (ru) | Лечение некистозных фиброзных (немуковисцидозных) бронхоэктазов | |
| JP2010540539A5 (https=) | ||
| Ghoshal et al. | Treatment of acute exacerbation of COPD | |
| CN117412756A (zh) | 磷霉素和粘菌素联合用于抗生物膜相关的细菌感染 | |
| Adkison et al. | Management of acute exacerbations of chronic obstructive pulmonary disease | |
| US20150265621A1 (en) | Treating Bronchiectasis With Doxofylline and Erdosteine | |
| Bajantri MD et al. | Pulmonary & Critical Care Insider: Issue 4 | |
| Sendy | Severity Assessment and Management of Chronic Obstructive Pulmonary Disease | |
| Hoppentocht et al. | Tolerability and pharmacokinetic evaluation of inhaled dry powder tobramycin free base in patients with non-cystic fibrosis bronchiectasis | |
| Wiley | Respiratory | |
| Bush et al. | 8. NEBULIZERS IN CYSTIC FIBROSIS AND NON-CF BRONCHIECTASIS IN CHILDREN AND ADULTS: THERAPIES | |
| Alffenaar et al. | Tolerability and Pharmacokinetic Evaluation of Inhaled Dry Powder Tobramycin Free Base in Non-Cystic Fibrosis Bronchiectasis Patients |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD Year of fee payment: 2 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20240726 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20240726 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250728 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250728 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20260324 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260401 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20260402 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20260402 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260402 |